Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial
RegulatoryapprovedMureva OMPositive
AI Analysis
Summary
Mureva Phototherapy Inc. announced FDA De Novo authorization for Mureva OM, a phototherapy device for severe oral mucositis, supported by a randomized sham-controlled pivotal trial. The company also published peer-reviewed results from the Mureva OM trial demonstrating significant reduction in severe oral mucositis.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
FDA granted De Novo authorization for Mureva OM
Importance:8/10
Sentiment:
0.90
FDA approvalDe Novo authorizationoral mucositisphototherapypivotal trialpeer-reviewed publication
Read the original article
Published by PR Newswire Pharma on September 10, 2026 1:00 PM